Pub Date : 2025-10-16DOI: 10.1016/j.molmet.2025.102271
Daniel A. Briere, Hongchang Qu, Katherine Lansu, Minxia Michelle He, Julie S. Moyers, Tamer Coskun, Annie Long, Dawn Allen, Libbey O'Farrell, Breanna Bowen, Edward Pratt, Beth Tidemann-Miller, Lai San Tham, Hilda Ibriga, Jorge Alsina-Fernandez, Kieren J. Mather, Axel Haupt, Shobha N. Bhattachar
Objectives
Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.
Methods
In vitro assays were performed in cell lines selectively expressing rat or human amylin 1 receptor (AMY1R), amylin 3 receptor (AMY3R), or calcitonin receptor (CTR). In vivo studies were conducted in rats and monkeys. A phase 1, randomized, placebo-controlled, participant/investigator-blinded trial evaluated the safety and tolerability of single-ascending eloralintide doses (0.04–12 mg) in healthy participants (NCT05295940).
Results
In vitro, eloralintide preferentially activated human AMY1R (12-fold > CTR, 11-fold > AMY3R), while in rats, both AMY1R and AMY3R were activated more potently than CTR. Eloralintide induced significantly less conditioned taste avoidance in lean rats than cagrilintide, a non-selective amylin receptor agonist (p < 0.05). Eloralintide dose dependently reduced food intake and lowered body weight, primarily through fat mass loss, in diet-induced obese rats. Eloralintide demonstrated favorable pharmacokinetics in both rats and monkeys. In the phase 1 trial, 48 healthy participants had a mean body mass index of 27.5 kg/m2. Nine participants in the eloralintide cohorts reported 16 adverse events, with most being mild (n = 15/16). Two participants reported 4 gastrointestinal events, including one moderate vomiting event. The pharmacokinetic profile of eloralintide supports once-weekly dosing. In eloralintide cohorts receiving single doses of 4 or 12 mg, week-4 mean percent change from baseline in body weight was −2.5% (p < 0.01) and −4.4% (p < 0.001), respectively, vs placebo (+0.6%).
Conclusions
Once-weekly dosing with eloralintide, an AMY1R-selective agonist, may offer a promising new therapeutic with favorable gastrointestinal tolerability for the treatment of obesity.
{"title":"Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept","authors":"Daniel A. Briere, Hongchang Qu, Katherine Lansu, Minxia Michelle He, Julie S. Moyers, Tamer Coskun, Annie Long, Dawn Allen, Libbey O'Farrell, Breanna Bowen, Edward Pratt, Beth Tidemann-Miller, Lai San Tham, Hilda Ibriga, Jorge Alsina-Fernandez, Kieren J. Mather, Axel Haupt, Shobha N. Bhattachar","doi":"10.1016/j.molmet.2025.102271","DOIUrl":"10.1016/j.molmet.2025.102271","url":null,"abstract":"<div><h3>Objectives</h3><div>Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.</div></div><div><h3>Methods</h3><div>In vitro assays were performed in cell lines selectively expressing rat or human amylin 1 receptor (AMY1R), amylin 3 receptor (AMY3R), or calcitonin receptor (CTR). In vivo studies were conducted in rats and monkeys. A phase 1, randomized, placebo-controlled, participant/investigator-blinded trial evaluated the safety and tolerability of single-ascending eloralintide doses (0.04–12 mg) in healthy participants (NCT05295940).</div></div><div><h3>Results</h3><div>In vitro, eloralintide preferentially activated human AMY1R (12-fold > CTR, 11-fold > AMY3R), while in rats, both AMY1R and AMY3R were activated more potently than CTR. Eloralintide induced significantly less conditioned taste avoidance in lean rats than cagrilintide, a non-selective amylin receptor agonist (p < 0.05). Eloralintide dose dependently reduced food intake and lowered body weight, primarily through fat mass loss, in diet-induced obese rats. Eloralintide demonstrated favorable pharmacokinetics in both rats and monkeys. In the phase 1 trial, 48 healthy participants had a mean body mass index of 27.5 kg/m<sup>2</sup>. Nine participants in the eloralintide cohorts reported 16 adverse events, with most being mild (n = 15/16). Two participants reported 4 gastrointestinal events, including one moderate vomiting event. The pharmacokinetic profile of eloralintide supports once-weekly dosing. In eloralintide cohorts receiving single doses of 4 or 12 mg, week-4 mean percent change from baseline in body weight was −2.5% (p < 0.01) and −4.4% (p < 0.001), respectively, vs placebo (+0.6%).</div></div><div><h3>Conclusions</h3><div>Once-weekly dosing with eloralintide, an AMY1R-selective agonist, may offer a promising new therapeutic with favorable gastrointestinal tolerability for the treatment of obesity.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"102 ","pages":"Article 102271"},"PeriodicalIF":6.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16DOI: 10.1016/j.molmet.2025.102269
Thu Van-Quynh Duong , Alexandra M. Yaw , Guoli Zhou , Niharika Sinha , Aneesh Sai Cherukuri , Duong Nguyen , Kylie Cataldo , Nicollette Ly , Aritro Sen , Lorenzo F. Sempere , Cara Detrie , Robert Seiler , I. Nicholas Olomu , Rene Cortese , Robert Long , Hanne M. Hoffmann
Due to significant risks of peripartum complications, pregnancies complicated by diabetes often require labor induction or augmentation with synthetic oxytocin. However, the efficacy of oxytocin is often compromised in diabetic pregnancies. Given that diabetes deregulates the body's circadian timekeeping system, our objective was to determine how time of day and the circadian clock gene, Bmal1, gate oxytocin efficacy. We compared oxytocin uterotonic efficacy in a smooth muscle-Bmal1 conditional knockout mouse (cKO), and a mouse model of food-induced gestational diabetes. We found that in wild-type mice, the oxytocin receptor is expressed in a time-of-day-dependent manner and is under the control of BMAL1. Both Bmal1 cKO and food-induced gestational diabetes mice, which presented with a downregulation of Bmal1 in the uterus, had decreased uterine contractility in response to oxytocin. To establish the translational value of these findings, we utilized an immortalized term human myometrial cell line. We determined that the time-of-day impacted oxytocin-induced myometrial contractility in vitro. Furthermore, we conducted a retrospective medical record analysis of 2,367 pregnant patients ≥39 weeks gestation undergoing induction of labor. We assessed the timing of labor induction and the impact of gestational diabetes mellitus on labor duration. Induction of labor in the morning compared to midnight was associated with a ∼1.5-hour and ∼7-hour shorter labor duration in controls and patients with gestational diabetes mellitus, respectively. In conclusion, circadian timing plays a key role in induction of labor and oxytocin responsiveness and should be considered when managing labor induction.
{"title":"Interaction between time-of-day and oxytocin efficacy in mice and humans with and without gestational diabetes","authors":"Thu Van-Quynh Duong , Alexandra M. Yaw , Guoli Zhou , Niharika Sinha , Aneesh Sai Cherukuri , Duong Nguyen , Kylie Cataldo , Nicollette Ly , Aritro Sen , Lorenzo F. Sempere , Cara Detrie , Robert Seiler , I. Nicholas Olomu , Rene Cortese , Robert Long , Hanne M. Hoffmann","doi":"10.1016/j.molmet.2025.102269","DOIUrl":"10.1016/j.molmet.2025.102269","url":null,"abstract":"<div><div>Due to significant risks of peripartum complications, pregnancies complicated by diabetes often require labor induction or augmentation with synthetic oxytocin. However, the efficacy of oxytocin is often compromised in diabetic pregnancies. Given that diabetes deregulates the body's circadian timekeeping system, our objective was to determine how time of day and the circadian clock gene, <em>Bmal1</em>, gate oxytocin efficacy. We compared oxytocin uterotonic efficacy in a smooth muscle-<em>Bmal1</em> conditional knockout mouse (cKO), and a mouse model of food-induced gestational diabetes. We found that in wild-type mice, the oxytocin receptor is expressed in a time-of-day-dependent manner and is under the control of BMAL1. Both <em>Bmal1</em> cKO and food-induced gestational diabetes mice, which presented with a downregulation of <em>Bmal1</em> in the uterus, had decreased uterine contractility in response to oxytocin. To establish the translational value of these findings, we utilized an immortalized term human myometrial cell line. We determined that the time-of-day impacted oxytocin-induced myometrial contractility <em>in vitro</em>. Furthermore, we conducted a retrospective medical record analysis of 2,367 pregnant patients ≥39 weeks gestation undergoing induction of labor. We assessed the timing of labor induction and the impact of gestational diabetes mellitus on labor duration. Induction of labor in the morning compared to midnight was associated with a ∼1.5-hour and ∼7-hour shorter labor duration in controls and patients with gestational diabetes mellitus, respectively. In conclusion, circadian timing plays a key role in induction of labor and oxytocin responsiveness and should be considered when managing labor induction.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"103 ","pages":"Article 102269"},"PeriodicalIF":6.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-15DOI: 10.1016/j.molmet.2025.102268
Sandra M. Ferreira , D. Walker Hagan , Austin E. Stis , Adrienne E. Widener , Alexandra E. Cuaycal , Chad Rancourt , Arabella G. Readey , Dylan S. Smurlick , Dongtao A. Fu , Martha Campbell–Thompson , Marjan Slak Rupnik , Edward A. Phelps
Objectives
Gamma-aminobutyric acid (GABA) is produced in pancreatic beta cells and is implicated in modulating islet function, yet its precise physiological role remains uncertain. This study aimed to determine the function of endogenous beta cell-derived GABA on insulin secretion and islet calcium dynamics by developing a conditional beta cell-specific knockout of GABA-synthesizing enzymes (GAD65 and GAD67).
Methods
Conditional knockout mice (GadβKO) lacking both GAD65 and GAD67 specifically in pancreatic beta cells were generated. Glucose-stimulated insulin secretion was measured in isolated islets and in vivo and islet Ca2+ oscillations were recorded using calcium imaging. The effects of GABA and its receptor agonists/antagonists were tested under various glucose conditions. Additional analyses were performed in high-fat diet-fed mice and human islets from donors with and without type 2 diabetes (T2D).
Results
GadβKO islets were devoid of GABA and showed excessive insulin secretion in response to glucose without anatomical changes in islet composition. These islets had defective Ca2+ oscillations, with prolonged active phases and reduced amplitudes. GABA application suppressed Ca2+ oscillations, an effect mediated by GABAA and GABAB receptors. High-fat diet-fed and T2D human islets were unresponsive to GABA and exhibited impaired Ca2+ oscillations.
Conclusions
This is the first study using a beta cell-specific GAD65/GAD67 knockout model. Endogenous beta cell-derived GABA is critical for modulating insulin secretion by maintaining proper Ca2+ oscillation dynamics. GABA signaling likely operates as a delayed negative feedback mechanism that reinforces oscillatory homeostasis in islets. The loss of GABA responsiveness, as seen in metabolic stress or T2D, may contribute to islet dysfunction. This work establishes GABA as a key regulator of islet rhythm and glucose responsiveness.
{"title":"Beta cell secreted GABA sets appropriate insulin secretion by modulating islet calcium oscillations","authors":"Sandra M. Ferreira , D. Walker Hagan , Austin E. Stis , Adrienne E. Widener , Alexandra E. Cuaycal , Chad Rancourt , Arabella G. Readey , Dylan S. Smurlick , Dongtao A. Fu , Martha Campbell–Thompson , Marjan Slak Rupnik , Edward A. Phelps","doi":"10.1016/j.molmet.2025.102268","DOIUrl":"10.1016/j.molmet.2025.102268","url":null,"abstract":"<div><h3>Objectives</h3><div>Gamma-aminobutyric acid (GABA) is produced in pancreatic beta cells and is implicated in modulating islet function, yet its precise physiological role remains uncertain. This study aimed to determine the function of endogenous beta cell-derived GABA on insulin secretion and islet calcium dynamics by developing a conditional beta cell-specific knockout of GABA-synthesizing enzymes (GAD65 and GAD67).</div></div><div><h3>Methods</h3><div>Conditional knockout mice (<em>Gad</em> <sup>βKO</sup>) lacking both GAD65 and GAD67 specifically in pancreatic beta cells were generated. Glucose-stimulated insulin secretion was measured in isolated islets and <em>in vivo</em> and islet Ca<sup>2+</sup> oscillations were recorded using calcium imaging. The effects of GABA and its receptor agonists/antagonists were tested under various glucose conditions. Additional analyses were performed in high-fat diet-fed mice and human islets from donors with and without type 2 diabetes (T2D).</div></div><div><h3>Results</h3><div><em>Gad</em> <sup>βKO</sup> islets were devoid of GABA and showed excessive insulin secretion in response to glucose without anatomical changes in islet composition. These islets had defective Ca<sup>2+</sup> oscillations, with prolonged active phases and reduced amplitudes. GABA application suppressed Ca<sup>2+</sup> oscillations, an effect mediated by GABA<sub>A</sub> and GABA<sub>B</sub> receptors. High-fat diet-fed and T2D human islets were unresponsive to GABA and exhibited impaired Ca<sup>2+</sup> oscillations.</div></div><div><h3>Conclusions</h3><div>This is the first study using a beta cell-specific GAD65/GAD67 knockout model. Endogenous beta cell-derived GABA is critical for modulating insulin secretion by maintaining proper Ca<sup>2+</sup> oscillation dynamics. GABA signaling likely operates as a delayed negative feedback mechanism that reinforces oscillatory homeostasis in islets. The loss of GABA responsiveness, as seen in metabolic stress or T2D, may contribute to islet dysfunction. This work establishes GABA as a key regulator of islet rhythm and glucose responsiveness.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"102 ","pages":"Article 102268"},"PeriodicalIF":6.6,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-15DOI: 10.1016/j.molmet.2025.102270
Jiameng Sun , Cassandra B. Higgins , Joshua A. Adams , Yiming Zhang , Shannon C. Kelly , Hyo-Jin Kim , Brian J. DeBosch
Objectives
Obesity is linked to metabolic disorders including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease. Lifestyle interventions, such as time-restricted feeding (TRF), have proven to be effective for long-term weight management. The metabolic effects of TRF are closely associated with circadian clock function in the liver. We previously demonstrated that the circadian gene Period 1 (Per1) mediates responses to acute fasting in both sexes. We therefore hypothesized that hepatocyte Per1 contributes to the long-term adaptations to repeated fasting exposure in the form of TRF, and investigated its role in diet-induced obesity in both sexes.
Methods
Male and female mice with or without hepatocyte Per1 (Per1fl/fl and Per1LKO) were subjected to either ad libitum feeding (ALF) or TRF restricted to the active phase (8 h/day).
Results
TRF attenuated Western diet-induced weight gain and peripheral and hepatic lipid accumulation, and improved heat production, metabolic substrate flexibility, and glucose homeostasis in Per1fl/fl and Per1LKO males. In contrast, hepatocyte Per1 was required for TRF-induced improvements in energy expenditure and peripheral and hepatic lipid accumulation in females. Surprisingly, TRF failed to significantly attenuate diet-induced weight gain or glucose and insulin tolerance in females independent of genotype. Transcriptomic data revealed sex-specific transcriptional responses to TRF and to hepatocyte-specific Per1 deletion. Specifically, genes involved in lipid metabolism were differentially regulated when comparing TRF-treated Per1fl/fl and Per1LKO female mice.
Conclusions
Hepatocyte Per1 mediates the energy, lipid, and glucose homeostatic effects of TRF, and this regulation is almost completely sex-dependent.
{"title":"Dimorphic regulation of time-restricted feeding effects by hepatocyte Period 1","authors":"Jiameng Sun , Cassandra B. Higgins , Joshua A. Adams , Yiming Zhang , Shannon C. Kelly , Hyo-Jin Kim , Brian J. DeBosch","doi":"10.1016/j.molmet.2025.102270","DOIUrl":"10.1016/j.molmet.2025.102270","url":null,"abstract":"<div><h3>Objectives</h3><div>Obesity is linked to metabolic disorders including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease. Lifestyle interventions, such as time-restricted feeding (TRF), have proven to be effective for long-term weight management. The metabolic effects of TRF are closely associated with circadian clock function in the liver. We previously demonstrated that the circadian gene <em>Period 1</em> (<em>Per1</em>) mediates responses to acute fasting in both sexes. We therefore hypothesized that hepatocyte <em>Per1</em> contributes to the long-term adaptations to repeated fasting exposure in the form of TRF, and investigated its role in diet-induced obesity in both sexes.</div></div><div><h3>Methods</h3><div>Male and female mice with or without hepatocyte <em>Per1</em> (<em>Per1</em><sup>fl/fl</sup> and <em>Per1</em><sup>LKO</sup>) were subjected to either <em>ad libitum</em> feeding (ALF) or TRF restricted to the active phase (8 h/day).</div></div><div><h3>Results</h3><div>TRF attenuated Western diet-induced weight gain and peripheral and hepatic lipid accumulation, and improved heat production, metabolic substrate flexibility, and glucose homeostasis in <em>Per1</em><sup>fl/fl</sup> and <em>Per1</em><sup>LKO</sup> males. In contrast, hepatocyte <em>Per1</em> was required for TRF-induced improvements in energy expenditure and peripheral and hepatic lipid accumulation in females. Surprisingly, TRF failed to significantly attenuate diet-induced weight gain or glucose and insulin tolerance in females independent of genotype. Transcriptomic data revealed sex-specific transcriptional responses to TRF and to hepatocyte-specific <em>Per1</em> deletion. Specifically, genes involved in lipid metabolism were differentially regulated when comparing TRF-treated <em>Per1</em><sup>fl/fl</sup> and <em>Per1</em><sup>LKO</sup> female mice.</div></div><div><h3>Conclusions</h3><div>Hepatocyte <em>Per1</em> mediates the energy, lipid, and glucose homeostatic effects of TRF, and this regulation is almost completely sex-dependent.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"102 ","pages":"Article 102270"},"PeriodicalIF":6.6,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-08DOI: 10.1016/j.molmet.2025.102267
Chung-Jui Yu , Ariane R. Pessentheiner , Sihao Liu , Sarah Wax , Marissa L. Maciej-Hulme , Chelsea D. Painter , Bastian Ramms , Daniel R. Sandoval , Anthony Quach , Natalie DeForest , G. Michelle Ducasa , Chiara Tognaccini , Caroline Labib , Norah Al-Azzam , Friederike Haumann , Greg Trieger , Patrick Secrest , Amit Majithia , Aaron C. Petrey , Kamil Godula , Philip L.S.M. Gordts
Obesity is the principal driver of insulin resistance, and lipodystrophy is also linked with insulin resistance, emphasizing the vital role of adipose tissue in glucose homeostasis. The quality of adipose tissue expansion is a critical determinant of insulin resistance predisposition, with individuals suffering from metabolic unhealthy adipose expansion exhibiting greater risk. Adipocytes are pivotal in orchestrating metabolic adjustments in response to nutrient intake and cell intrinsic factors that positively regulate these adjustments are key to prevent Type-2 diabetes. Employing unique genetic mouse models, we established the critical involvement of heparan sulfate (HS), a fundamental element of the adipocyte glycocalyx, in upholding glucose homeostasis during dietary stress. Genetic models that compromise adipocyte HS accelerate the development of high-fat diet-induced hyperglycemia and insulin resistance, independent of weight gain. Mechanistically, we show that perturbations in adipocyte HS disrupts endogenous FGF1 signaling, a key nutrient-sensitive effector. Furthermore, compromising adipocyte HS composition detrimentally impacts FGF1-FGFR1-mediated endocrinization, with no significant improvement observed in glucose homeostasis. Our data establish adipocyte HS composition as a determinant of Type 2 diabetes susceptibility and the critical dependency of the endogenous adipocyte FGF1 metabolic pathway on HS.
{"title":"Adipocyte heparan sulfate determines type 2 diabetes susceptibility in mice via FGF1-Mediated glucose regulation","authors":"Chung-Jui Yu , Ariane R. Pessentheiner , Sihao Liu , Sarah Wax , Marissa L. Maciej-Hulme , Chelsea D. Painter , Bastian Ramms , Daniel R. Sandoval , Anthony Quach , Natalie DeForest , G. Michelle Ducasa , Chiara Tognaccini , Caroline Labib , Norah Al-Azzam , Friederike Haumann , Greg Trieger , Patrick Secrest , Amit Majithia , Aaron C. Petrey , Kamil Godula , Philip L.S.M. Gordts","doi":"10.1016/j.molmet.2025.102267","DOIUrl":"10.1016/j.molmet.2025.102267","url":null,"abstract":"<div><div>Obesity is the principal driver of insulin resistance, and lipodystrophy is also linked with insulin resistance, emphasizing the vital role of adipose tissue in glucose homeostasis. The quality of adipose tissue expansion is a critical determinant of insulin resistance predisposition, with individuals suffering from metabolic unhealthy adipose expansion exhibiting greater risk. Adipocytes are pivotal in orchestrating metabolic adjustments in response to nutrient intake and cell intrinsic factors that positively regulate these adjustments are key to prevent Type-2 diabetes. Employing unique genetic mouse models, we established the critical involvement of heparan sulfate (HS), a fundamental element of the adipocyte glycocalyx, in upholding glucose homeostasis during dietary stress. Genetic models that compromise adipocyte HS accelerate the development of high-fat diet-induced hyperglycemia and insulin resistance, independent of weight gain. Mechanistically, we show that perturbations in adipocyte HS disrupts endogenous FGF1 signaling, a key nutrient-sensitive effector. Furthermore, compromising adipocyte HS composition detrimentally impacts FGF1-FGFR1-mediated endocrinization, with no significant improvement observed in glucose homeostasis. Our data establish adipocyte HS composition as a determinant of Type 2 diabetes susceptibility and the critical dependency of the endogenous adipocyte FGF1 metabolic pathway on HS.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"102 ","pages":"Article 102267"},"PeriodicalIF":6.6,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-04DOI: 10.1016/j.molmet.2025.102264
Martina Beretta , Calum S. Vancuylenburg , Riya Shrestha , Ellen M. Olzomer , Brenna Osborne , Mingyan Zhou , Suri Zhang , Adam Hargreaves , Frances L. Byrne , Kyle L. Hoehn
Objectives
Acetyl-CoA carboxylase enzymes ACC1 and ACC2 promote liver fat storage. Accordingly, ACC inhibition represents a strategy to reverse fatty liver disease and related disorders. Human and rodent studies show that targeting both ACC isotypes can reverse some fatty liver phenotypes, but also result in unwanted metabolic phenotypes including hypertriglyceridemia. The objective of this study was to determine whether liver-selective genetic inhibition of ACC1 or ACC2 individually can reverse fatty liver disease phenotypes without adverse metabolic phenotypes in a mouse model of fatty liver disease.
Methods
Four genotypes of male C57BL/6J mice floxed for ACC1, ACC2, both ACC alleles, or no ACC alleles were fed an Amylin diet for 28 weeks to induce fatty liver disease. After 20 weeks of Amylin feeding, ACC genes were deleted in the liver by adeno-associated virus 8 (AAV8)-mediated Cre recombinase expression. Mice were metabolically phenotyped and liver disease was assessed by histopathology.
Results
Dual inhibition of ACC enzymes was necessary to achieve significant reversal of fatty liver disease and fibrosis; however, it also caused hypertriglyceridemia, weight gain, and glucose intolerance. ACC1 inhibition alone resulted in partial reversal of fatty liver disease phenotypes but drove all undesired metabolic phenotypes. In contrast, ACC2 inhibition alone had minimal effect on fatty liver, fibrosis, or metabolic phenotypes.
Conclusions
Our results indicate that complete inhibition of liver ACC activity is required to resolve fatty liver disease and fibrosis, with ACC1 inhibition being the dominant driver of unwanted metabolic dysregulation. Accordingly, selective inhibition of ACC2 with partial inhibition of ACC1 may represent a refined future approach to reverse fatty liver disease phenotypes while minimizing metabolic dysregulation.
{"title":"Isotype-selective roles of hepatic acetyl-CoA carboxylases in a mouse model of fatty liver disease","authors":"Martina Beretta , Calum S. Vancuylenburg , Riya Shrestha , Ellen M. Olzomer , Brenna Osborne , Mingyan Zhou , Suri Zhang , Adam Hargreaves , Frances L. Byrne , Kyle L. Hoehn","doi":"10.1016/j.molmet.2025.102264","DOIUrl":"10.1016/j.molmet.2025.102264","url":null,"abstract":"<div><h3>Objectives</h3><div>Acetyl-CoA carboxylase enzymes ACC1 and ACC2 promote liver fat storage. Accordingly, ACC inhibition represents a strategy to reverse fatty liver disease and related disorders. Human and rodent studies show that targeting both ACC isotypes can reverse some fatty liver phenotypes, but also result in unwanted metabolic phenotypes including hypertriglyceridemia. The objective of this study was to determine whether liver-selective genetic inhibition of ACC1 or ACC2 individually can reverse fatty liver disease phenotypes without adverse metabolic phenotypes in a mouse model of fatty liver disease.</div></div><div><h3>Methods</h3><div>Four genotypes of male C57BL/6J mice floxed for ACC1, ACC2, both ACC alleles, or no ACC alleles were fed an Amylin diet for 28 weeks to induce fatty liver disease. After 20 weeks of Amylin feeding, ACC genes were deleted in the liver by adeno-associated virus 8 (AAV8)-mediated Cre recombinase expression. Mice were metabolically phenotyped and liver disease was assessed by histopathology.</div></div><div><h3>Results</h3><div>Dual inhibition of ACC enzymes was necessary to achieve significant reversal of fatty liver disease and fibrosis; however, it also caused hypertriglyceridemia, weight gain, and glucose intolerance. ACC1 inhibition alone resulted in partial reversal of fatty liver disease phenotypes but drove all undesired metabolic phenotypes. In contrast, ACC2 inhibition alone had minimal effect on fatty liver, fibrosis, or metabolic phenotypes.</div></div><div><h3>Conclusions</h3><div>Our results indicate that complete inhibition of liver ACC activity is required to resolve fatty liver disease and fibrosis, with ACC1 inhibition being the dominant driver of unwanted metabolic dysregulation. Accordingly, selective inhibition of ACC2 with partial inhibition of ACC1 may represent a refined future approach to reverse fatty liver disease phenotypes while minimizing metabolic dysregulation.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"102 ","pages":"Article 102264"},"PeriodicalIF":6.6,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-03DOI: 10.1016/j.molmet.2025.102265
Kristin Röhrborn , Anne Hoffmann , Andrea Lorenz , Peter Kovacs , Tobias Hagemann , Paul Czechowski , Maria Sehm , Annette Horstmann , Michael Stumvoll , Matthias Blüher , Imke Schamarek , Kerstin Rohde-Zimmermann
Background
Extracellular vesicles (EVs), conveyors of microRNAs, have recently been linked to obesity. As taste is a potent driver of eating behaviour and food intake, it's connection to EVs is of increasing interest. This study aimed at deciphering the salivary EV-microRNA profile in relation to taste perception and metabolic pathways of obesity.
Methods
Small RNA sequencing was performed on isolated salivary EVs of 90 participants from the Obese-Taste-Bud study. Pathway enrichment and association analyses were conducted to link identified microRNAs to taste recognition, eating behaviour, food intake and various anthropometric-, metabolic- and oral health parameter.
Results
The 626 identified microRNAs clustered into pathways related to energy regulation, obesity and diabetes, cell signaling and taste perception. The top three enriched microRNAs are miR-1246, miR-1290 and miR-148a-3p which showed significant associations with fasting blood glucose and cholesterol level, anthropometrics and blood pressure (p < 0.05). Additionally, these microRNAs associate with trait eating behaviour (p < 0.05). Several other microRNAs were linked to differences in taste recognition scores and are further related to parameters of glucose metabolism and periodontal health, salivary insulin level or food intake (p < 0.05).
Conclusions
This study, one of the largest on salivary EVs, supports an interrelation of EV's microRNA load with metabolism, eating behaviour and taste recognition offering potential targets for obesity intervention.
{"title":"Salivary extracellular vesicle-derived microRNAs are related to variances in parameters of obesity, taste and eating behaviour","authors":"Kristin Röhrborn , Anne Hoffmann , Andrea Lorenz , Peter Kovacs , Tobias Hagemann , Paul Czechowski , Maria Sehm , Annette Horstmann , Michael Stumvoll , Matthias Blüher , Imke Schamarek , Kerstin Rohde-Zimmermann","doi":"10.1016/j.molmet.2025.102265","DOIUrl":"10.1016/j.molmet.2025.102265","url":null,"abstract":"<div><h3>Background</h3><div>Extracellular vesicles (EVs), conveyors of microRNAs, have recently been linked to obesity. As taste is a potent driver of eating behaviour and food intake, it's connection to EVs is of increasing interest. This study aimed at deciphering the salivary EV-microRNA profile in relation to taste perception and metabolic pathways of obesity.</div></div><div><h3>Methods</h3><div>Small RNA sequencing was performed on isolated salivary EVs of 90 participants from the Obese-Taste-Bud study. Pathway enrichment and association analyses were conducted to link identified microRNAs to taste recognition, eating behaviour, food intake and various anthropometric-, metabolic- and oral health parameter.</div></div><div><h3>Results</h3><div>The 626 identified microRNAs clustered into pathways related to energy regulation, obesity and diabetes, cell signaling and taste perception. The top three enriched microRNAs are miR-1246, miR-1290 and miR-148a-3p which showed significant associations with fasting blood glucose and cholesterol level, anthropometrics and blood pressure (p < 0.05). Additionally, these microRNAs associate with trait eating behaviour (p < 0.05). Several other microRNAs were linked to differences in taste recognition scores and are further related to parameters of glucose metabolism and periodontal health, salivary insulin level or food intake (p < 0.05).</div></div><div><h3>Conclusions</h3><div>This study, one of the largest on salivary EVs, supports an interrelation of EV's microRNA load with metabolism, eating behaviour and taste recognition offering potential targets for obesity intervention.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"102 ","pages":"Article 102265"},"PeriodicalIF":6.6,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-03DOI: 10.1016/j.molmet.2025.102262
Laura Braud , Manuel Bernabe , Julien Vernerey , Antonio M.A. Miranda , Andrea Dominguez , Dmitri Churikov , Manon Richaud , Frédéric Jourquin , Liam Mc Allan , Christophe Lachaud , Jesus Gil , Will Scott , Vincent Géli
Background and aims
Adipose tissue (AT) senescence, induced by obesity or aging, leads to a reduced capacity for tissue remodeling and a chronic pro-inflammatory state, which leads to the onset of metabolic pathologies. Cellular senescence is triggered by various stresses, in particular excessive shortening of telomeres, which activates the p21 pathway and leads to the arrest of the cell cycle. We used the mouse model p21+/Tert expressing TERT from the Cdkn1a locus to investigate whether counteracting telomere shortening by telomerase (TERT) specifically in pre-senescent cells could improve obesity-induced metabolic disorders.
Results
Our study demonstrates that conditional expression of TERT reduces insulin-resistance and glucose intolerance associated with obesity. In AT, this is accompanied by a decrease in the number of senescent p21-positive cells, very short telomeres, and oxidative DNA damage. Single nucleus RNA-seq data reveal TERT expression attenuates senescence induced by HFD in particular in adipose stem and progenitor cells (ASPC). We demonstrate that ASPC expansion and differentiation are promoted in p21+/Tert obese mice, thereby improving AT plasticity. Furthermore, we show that TERT expression enhances mitochondrial function and alleviates oxidative stress in ASPC. This process contributes to the AT hyperplasia with increased number of adipocytes which has been shown to have a protective effect against obesity-associated metabolic disorders.
Conclusions
These results underscore TERT's role in mitigating obesity-related metabolic dysfunction. Conditional TERT expression may therefore represent as a promising therapeutic strategy for obesity-associated metabolic disorders.
{"title":"TERT expression attenuates metabolic disorders in obese mice by promoting adipose stem and progenitor cell expansion and differentiation","authors":"Laura Braud , Manuel Bernabe , Julien Vernerey , Antonio M.A. Miranda , Andrea Dominguez , Dmitri Churikov , Manon Richaud , Frédéric Jourquin , Liam Mc Allan , Christophe Lachaud , Jesus Gil , Will Scott , Vincent Géli","doi":"10.1016/j.molmet.2025.102262","DOIUrl":"10.1016/j.molmet.2025.102262","url":null,"abstract":"<div><h3>Background and aims</h3><div>Adipose tissue (AT) senescence, induced by obesity or aging, leads to a reduced capacity for tissue remodeling and a chronic pro-inflammatory state, which leads to the onset of metabolic pathologies. Cellular senescence is triggered by various stresses, in particular excessive shortening of telomeres, which activates the p21 pathway and leads to the arrest of the cell cycle. We used the mouse model p21<sup>+/Tert</sup> expressing TERT from the Cdkn1a locus to investigate whether counteracting telomere shortening by telomerase (TERT) specifically in pre-senescent cells could improve obesity-induced metabolic disorders.</div></div><div><h3>Results</h3><div>Our study demonstrates that conditional expression of TERT reduces insulin-resistance and glucose intolerance associated with obesity. In AT, this is accompanied by a decrease in the number of senescent p21-positive cells, very short telomeres, and oxidative DNA damage. Single nucleus RNA-seq data reveal TERT expression attenuates senescence induced by HFD in particular in adipose stem and progenitor cells (ASPC). We demonstrate that ASPC expansion and differentiation are promoted in p21<sup>+/Tert</sup> obese mice, thereby improving AT plasticity. Furthermore, we show that TERT expression enhances mitochondrial function and alleviates oxidative stress in ASPC. This process contributes to the AT hyperplasia with increased number of adipocytes which has been shown to have a protective effect against obesity-associated metabolic disorders.</div></div><div><h3>Conclusions</h3><div>These results underscore TERT's role in mitigating obesity-related metabolic dysfunction. Conditional TERT expression may therefore represent as a promising therapeutic strategy for obesity-associated metabolic disorders.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"102 ","pages":"Article 102262"},"PeriodicalIF":6.6,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-07-23DOI: 10.1016/j.molmet.2025.102220
Jessica J Rea, Clarissa M Liu, Anna M R Hayes, Rita Ohan, Grace M Schwartz, Alexander G Bashaw, Molly E Klug, Lea Decarie-Spain, Yedam Park, Alicia E Kao, Valery Grinevich, Scott E Kanoski
Objectives: Oxytocin (OT) is a neuropeptide produced in the paraventricular (PVH) and supraoptic (SON) nuclei of the hypothalamus. Either peripheral or central OT administration reduces food intake through reductions in meal size. However, pharmacological approaches do not differentiate whether OT's influence on food intake is mediated by OT neurons located in the PVH vs. the SON. Here we address this gap using both gain- and loss-of-function approaches targeting OT neurons.
Methods: OT neuron-specific designer receptors exclusively activated by designer drugs (DREADDs) were targeted in either the PVH or SON in rats, thus allowing for evaluation of caloric intake following selective activation of OT neurons separately in each nucleus. To examine the physiological role of distinct OT neuron populations in eating behavior, a viral-mediated approach was used to silence synaptic transmission of OT neurons separately in either the PVH or SON.
Results: DREADDs-mediated excitation of PVH OT neurons reduced consumption of standard chow via reductions in meal size. On the contrary, SON OT neuron activation had the opposite effect by increasing standard chow consumption. Consistent with these opposing outcomes, activation of PVH and SON OT neurons simultaneously had minimal effects on food intake. Additional results from chronic loss-of-function experiments reveal that PVH OT neuron silencing significantly increased consumption of a high fat and high sugar diet by increasing meal size whereas SON OT neuron silencing reduced chow consumption by decreasing meal size.
Conclusions: Collectively these findings suggest that PVH and SON OT neurons differentially modulate food intake by either reducing or increasing caloric consumption, respectively.
{"title":"Oxytocin neurons in the paraventricular and supraoptic hypothalamic nuclei bidirectionally modulate food intake.","authors":"Jessica J Rea, Clarissa M Liu, Anna M R Hayes, Rita Ohan, Grace M Schwartz, Alexander G Bashaw, Molly E Klug, Lea Decarie-Spain, Yedam Park, Alicia E Kao, Valery Grinevich, Scott E Kanoski","doi":"10.1016/j.molmet.2025.102220","DOIUrl":"10.1016/j.molmet.2025.102220","url":null,"abstract":"<p><strong>Objectives: </strong>Oxytocin (OT) is a neuropeptide produced in the paraventricular (PVH) and supraoptic (SON) nuclei of the hypothalamus. Either peripheral or central OT administration reduces food intake through reductions in meal size. However, pharmacological approaches do not differentiate whether OT's influence on food intake is mediated by OT neurons located in the PVH vs. the SON. Here we address this gap using both gain- and loss-of-function approaches targeting OT neurons.</p><p><strong>Methods: </strong>OT neuron-specific designer receptors exclusively activated by designer drugs (DREADDs) were targeted in either the PVH or SON in rats, thus allowing for evaluation of caloric intake following selective activation of OT neurons separately in each nucleus. To examine the physiological role of distinct OT neuron populations in eating behavior, a viral-mediated approach was used to silence synaptic transmission of OT neurons separately in either the PVH or SON.</p><p><strong>Results: </strong>DREADDs-mediated excitation of PVH OT neurons reduced consumption of standard chow via reductions in meal size. On the contrary, SON OT neuron activation had the opposite effect by increasing standard chow consumption. Consistent with these opposing outcomes, activation of PVH and SON OT neurons simultaneously had minimal effects on food intake. Additional results from chronic loss-of-function experiments reveal that PVH OT neuron silencing significantly increased consumption of a high fat and high sugar diet by increasing meal size whereas SON OT neuron silencing reduced chow consumption by decreasing meal size.</p><p><strong>Conclusions: </strong>Collectively these findings suggest that PVH and SON OT neurons differentially modulate food intake by either reducing or increasing caloric consumption, respectively.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102220"},"PeriodicalIF":6.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-07-24DOI: 10.1016/j.molmet.2025.102221
Jazmin Osorio-Mendoza, Jana-Thabea Kiehn, Sarah Stenger, Keno O Heinen, Laura Griewahn, Christiane E Koch, Undine Haferkamp, Violetta Pilorz, Johanna L Barclay, Parth Joshi, Lisbeth Harder, Olaf Jöhren, Peter Kühnen, Gregor Eichele, Henrik Oster
Objective: The circadian clock anticipates daily repetitive events to adapt physiological processes. In mammals, the circadian system consists of a master clock in the suprachiasmatic nucleus (SCN), which synchronizes subordinate tissue clocks, including extra-SCN central nervous system (CNS) clocks involved in functions such as sleep and appetite regulation. Appetite is controlled by both homeostatic and non-homeostatic (hedonic) circuits. Homeostatic appetite addresses energy needs, while hedonic feeding targets cravings for palatable, calorie-dense foods. The adipokine leptin is a major appetite regulator, interacting with the circadian clock. Although leptin's role in satiation through its action in the mediobasal hypothalamus (MBH) is well established, its involvement in the circadian regulation of feeding remains poorly understood. We hypothesized that circadian gating of leptin signaling in the CNS controls homeostatic and hedonic appetite across the day.
Methods: We analyzed food intake rhythms in mice with a loss of leptin (ob/ob mice) or clock function (Per1/2 or Bmal1 KO) and in mice with specific disruption of leptin circadian gating in the CNS (ObRb.Bmal1).
Results: We found that in leptin-deficient mice hedonic appetite increases specifically in the early rest phase. In contrast, clock-deficient Per1/2 mutant mice exhibit blunted rhythms in both hedonic and homeostatic appetite control. Finally, when clock function is disrupted in leptin-sensitive neurons only, mice display a lower sensitivity to palatable food, along with reduced initial weight gain and adipose hypertrophy under obesogenic diet conditions.
Conclusions: Our data describe a local clock-controlled central leptin gating mechanism that modulates hedonic food intake rhythms and impacts metabolic homeostasis.
{"title":"Regulation of hedonic feeding rhythms by circadian clocks in leptin-receptive neurons.","authors":"Jazmin Osorio-Mendoza, Jana-Thabea Kiehn, Sarah Stenger, Keno O Heinen, Laura Griewahn, Christiane E Koch, Undine Haferkamp, Violetta Pilorz, Johanna L Barclay, Parth Joshi, Lisbeth Harder, Olaf Jöhren, Peter Kühnen, Gregor Eichele, Henrik Oster","doi":"10.1016/j.molmet.2025.102221","DOIUrl":"10.1016/j.molmet.2025.102221","url":null,"abstract":"<p><strong>Objective: </strong>The circadian clock anticipates daily repetitive events to adapt physiological processes. In mammals, the circadian system consists of a master clock in the suprachiasmatic nucleus (SCN), which synchronizes subordinate tissue clocks, including extra-SCN central nervous system (CNS) clocks involved in functions such as sleep and appetite regulation. Appetite is controlled by both homeostatic and non-homeostatic (hedonic) circuits. Homeostatic appetite addresses energy needs, while hedonic feeding targets cravings for palatable, calorie-dense foods. The adipokine leptin is a major appetite regulator, interacting with the circadian clock. Although leptin's role in satiation through its action in the mediobasal hypothalamus (MBH) is well established, its involvement in the circadian regulation of feeding remains poorly understood. We hypothesized that circadian gating of leptin signaling in the CNS controls homeostatic and hedonic appetite across the day.</p><p><strong>Methods: </strong>We analyzed food intake rhythms in mice with a loss of leptin (ob/ob mice) or clock function (Per1/2 or Bmal1 KO) and in mice with specific disruption of leptin circadian gating in the CNS (ObRb.Bmal1).</p><p><strong>Results: </strong>We found that in leptin-deficient mice hedonic appetite increases specifically in the early rest phase. In contrast, clock-deficient Per1/2 mutant mice exhibit blunted rhythms in both hedonic and homeostatic appetite control. Finally, when clock function is disrupted in leptin-sensitive neurons only, mice display a lower sensitivity to palatable food, along with reduced initial weight gain and adipose hypertrophy under obesogenic diet conditions.</p><p><strong>Conclusions: </strong>Our data describe a local clock-controlled central leptin gating mechanism that modulates hedonic food intake rhythms and impacts metabolic homeostasis.</p>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102221"},"PeriodicalIF":6.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}